Cargando…

Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country

Having multiple dimensions, uncertainties and several stakeholders, the costly pharmacogenomics (PGx) is associated with dynamic implementation complexities. Identification of these challenges is critical to harness its full potential, especially in developing countries with fragile healthcare syste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayati, Nayyereh, Afzali, Monireh, Hasanzad, Mandana, Kebriaeezadeh, Abbas, Rajabzadeh, Ali, Nikfar, Shekoufeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shaheed Beheshti University of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842599/ https://www.ncbi.nlm.nih.gov/pubmed/35194431 http://dx.doi.org/10.22037/ijpr.2021.114899.15091

Ejemplares similares

Short and long term impacts of COVID-19 on the pharmaceutical sector
por: Ayati, Nayyereh, et al.
Publicado: (2020)

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries
por: Kebriaeezadeh, Abbas, et al.
Publicado: (2013)

Pharmacists Remuneration Models in Iran and Selected Countries: a Comparative Study
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

Direct and indirect cost of managing Alzheimer’s disease in the Islamic Republic of Iran
por: Aajami, Zahra, et al.
Publicado: (2019)

Assessment of the vaccine industry in Iran in context of accession to WTO: a survey study
por: Hashemi Meshkini, Amir, et al.
Publicado: (2012)

Personalized treatment options for thyroid cancer: current perspectives
por: Khatami, Fatemeh, et al.
Publicado: (2019)

Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran
por: Nikfar, Shekoufeh, et al.
Publicado: (2005)

Precision Medicine in Non Communicable Diseases
por: Hasanzad, Mandana, et al.
Publicado: (2019)

A model for developing a decision support system to simulate national drug policy indicators
por: Abdollahiasl, Akbar, et al.
Publicado: (2011)

Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children
por: Gharibnaseri, Zahra, et al.
Publicado: (2012)

Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2023)

Hurdles of publication: to authors to overcome
por: Mohammadhassanzadeh, Hafez, et al.
Publicado: (2014)

Consistent defined threshold and equity in health
por: Nikfar, Shekoufeh, et al.
Publicado: (2015)

Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran
por: Teimouri, Fatemeh, et al.
Publicado: (2017)

Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies
por: Rezvanfar, Mohammad Ali, et al.
Publicado: (2013)

COVID-19 lockdown implementation in Ghana: lessons learned and hurdles to overcome
por: Assan, Abraham, et al.
Publicado: (2022)

A Scoping Review of Different Methods of Assessing the Impact of New Medical Technologies at Early Stages of Development
por: Goudarzi, Zahra, et al.
Publicado: (2021)

Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges
por: Arwood, MJ, et al.
Publicado: (2016)

Interchangeability of Biosimilars: Overcoming the Final Hurdles
por: Barbier, Liese, et al.
Publicado: (2021)

Financial perspective of private pharmacies in Tehran (Iran); is it a lucrative business?
por: Keshavarz, Khosro, et al.
Publicado: (2012)

A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience
por: Keshavarz, Khosro, et al.
Publicado: (2013)

A Systematic Review of Discrete Choice Experiment Studies in Rheumatoid Arthritis Biological Medicines
por: Zartab, Saman, et al.
Publicado: (2021)

Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

Cost-utility of Protocols of BFM-ALL and UK-ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran
por: HAYATI, Hadi, et al.
Publicado: (2018)

Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation
por: Chehelgerdi, Mohammad, et al.
Publicado: (2023)

Esophageal Cancer: Overcome the Hurdles and Reach for the Cure
por: Kim, Hong Kwan, et al.
Publicado: (2020)

Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

A system dynamics model for national drug policy
por: Abdollahiasl, Akbar, et al.
Publicado: (2014)

A review on inputs and outputs in determining the efficiency of universities of medical sciences by data envelopment analysis method
por: Mojahedian, Mohammad M., et al.
Publicado: (2020)

From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2014)

A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
por: Alavian, Seyed Moayed, et al.
Publicado: (2016)

Commercialization of biopharmaceutical knowledge in Iran; challenges and solutions
por: Nassiri-Koopaei, Nasser, et al.
Publicado: (2014)

Childhood immunisation in South Asia – overcoming the hurdles to progress
por: Hasman, Andreas, et al.
Publicado: (2016)

Standardisation and controls, why can’t we overcome the hurdles?
por: Niesters, Hubert G.M., et al.
Publicado: (2004)

DRUG REPURPOSING—Overcoming the translational hurdles to clinical use
por: Martin, Jennifer H., et al.
Publicado: (2019)

BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles
por: Dunlop, William C. N., et al.
Publicado: (2016)

Small interfering RNA for cancer treatment: overcoming hurdles in delivery
por: Charbe, Nitin Bharat, et al.
Publicado: (2020)

Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery
por: Teng, Xin-Qi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jgckdk5k60mlastk27af7lt2je